ALSIP, IL / ACCESSWIRE / August 28, 2023 / Capstone Holding Corp. (OTCQB:CAPS) ("the Company")

Effective August 25, 2023, Omar Rabbani resigned in good standing as Chief Financial Officer of the Company.

Edward Schultz, formerly Director of Financial Reporting at the Company, has been elected by the Company's Board to serve as Vice President, Treasurer and Chief Financial Officer effective August 25, 2023.

Please see the Company's Annual Report filed with the OTCQB Markets for further information.

About Capstone Holding Corp.

Capstone Therapeutics was a biotechnology company committed to developing novel therapeutic peptides aimed at helping patients with under-served medical conditions. The drug development business has been discontinued and the Company's name changed to Capstone Holding Corp. The Company's primary business activities presently include the operations of TotalStone, LLC, a construction materials company, and managing its equity interest in Diamond Products, LLC through its ownership of Capstone Beta, LLC, a member of Diamond Products Holdings, LLC.

Capstone's corporate headquarters is located in Alsip, Illinois. For more information, please visit the Company's website: www.capstonethx.com.

Statements in this press release or otherwise attributable to Capstone regarding our business that are not historical facts are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted results. These risks include the factors discussed in our Annual Report for the fiscal year ended December 31, 2022, and other documents we filed with the U.S. Securities and Exchange Commission or OTCQB Markets.

FOR FURTHER INFORMATION:

Investor Relations
(708) 371-0660
investorinquiries@capstonethx.com

SOURCE: Capstone Therapeutics Corp